Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2024 Earnings Call March 4, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Matthew Parisi - KeyBanc Capital Markets Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Jennifer Henry, Senior Vice President of Marketing.
Conestoga Capital Advisors, an asset management firm, has published its investor letter for the fourth quarter of 2024, which you can download here. For the second year in a row, U.S. stock indices finished the year with returns in the double digits, following modest gains in the last quarter of 2024. The company's investment strategies faced challenges due to the excitement surrounding various investments.
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q3 2024 Earnings Conference Call November 7, 2024 5:30 PM ET Company Participants Jennifer Henry – Senior Vice President-Marketing Stephen Gunstream – President and Chief Executive Officer Matt Lowell – Chief Financial Officer Conference Call Participants Chad Wiatrowski – TD Cowen Lucas Baranowski – KeyBanc Capital Markets Vidyun Bais – BTIG Jacob Johnson – Stephens Matt Larew – William Blair Operator Hello, and welcome to Alpha Teknova Third Quarter 2024 Financial Results. At this time all participants are in a listen-only mode.
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market.
Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Second quarter 2024 total revenue was $9.6 million, up 3% sequentially Raised $15.4 million of equity capital in July 2024 Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade Company reaffirms 2024 revenue guidance of $35-38 million
HOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2024, on Tuesday, August 13, 2024, following the close of market.
HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.
HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based on the Nasdaq Official Closing Price of Teknova's common stock on July 11, 2024.